Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Jan 22;11:2118. doi: 10.1038/s41598-021-81253-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2021

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Integrin antibody screening and assay development. (A) Staged efforts to screen integrin antibodies from human naïve IgG library by using Adimab’s yeast display platform. (B) IgG-expressing yeast clone selection process. The X-axis represents integrin binding and the Y-axis reflects antibody expression. Yeast cell population with strong antigen binding (boxed) was sorted out for the next round of selection. (C) Cell-based ELISA (CELISA) binding assays were used as the primary screen for integrin antibody selection. Dose-dependent binding of the benchmarking integrin antibody mAb-24 to various integrin-expressing CHOK1 cells was shown. (D) AlphaLISA integrin-ligand binding assays were used for in vitro functional screen. Dose-dependent inhibition of human integrin-ligand binding by MK-0429 in AlphaLISA assay panel.